Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

<h3>Introduction:</h3><p dir="ltr">Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hen...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Alaa Rahhal (14150403) (author)
مؤلفون آخرون:	Mostafa Najim (14150400) (author), Amer Hussein Aljundi (17945567) (author), Ahmed Mahfouz (737928) (author), Sumaya Mehdar Alyafei (17945570) (author), Ahmed Awaisu (5121473) (author), Mhd, Baraa Habib (17945573) (author), Ibrahim Obeidat (17945576) (author), Mohanad Mohammed Faisal (17945579) (author), Meshaal Ali Alanzi (17945582) (author), Arun Prabhakaran Nair (17945585) (author), Areeg Elhassan (17945588) (author), Abdullah Al-Dushain (17945591) (author), Alaaeldin Abdelmajid Abdelmajid (17945594) (author), Ahmed Elfadil Abdelgader (17945597) (author), Ahmed Mahmoud Ahmed Moursi (17945600) (author), Ahmad Eid Nazzal Alharafsheh (17945603) (author), Mohd Ragheb Abou Kamar (17945606) (author), Wael Goravey (14777254) (author), Amr Salah Omar (17151028) (author), Mohammed Abukhattab (9538614) (author), Mohamad Yahya Khatib (14152437) (author), Mohamed Gaafar Mohamedali (17945609) (author), Muna A. Rahman AlMaslamani (17945612) (author), Samar Alemadi (14152899) (author)
منشور في:	2022
الموضوعات:	Biomedical and clinical sciences Clinical sciences colchicine COVID-19 IL-6 antagonists severe pneumonia tocilizumab
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

مواد مشابهة